Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo

References

• Berthold DR, Pond GR, Soban F, et al. (2008). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–5
   PubMed Web of Science ®Google Scholar
• Bissett D, Setanoians A, Cassidy J, et al. (1993). Phase I and pharmacokinetic study of taxotere (RP56976) administered as a 24-hour infusion. Cancer Res 53:523–7
   PubMed Web of Science ®Google Scholar
• Burgos-Morón E, Calderón-Montaño JM, Salvador J, et al. (2010). The dark side of curcumin. Int J Cancer 126:1771–5
   PubMed Web of Science ®Google Scholar
• Chan JM, Zhang L, Yuet KP, et al. (2009). PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30:1627–34
   PubMed Web of Science ®Google Scholar
• Chandratre SS, Dash AK. (2015). Multifunctional nanoparticles for prostate cancer therapy. AAPS PharmSciTech 16:98–107
   PubMed Web of Science ®Google Scholar
• Chen QH. (2015). Curcumin-based anti-prostate cancer agents. Anticancer Agents Med Chem 15:138–56
   PubMed Web of Science ®Google Scholar
• Dorai T, Diouri J, O'Shea O, et al. (2014). Curcumin inhibits prostate cancer bone metastasis by up-regulating bone morphogenic protein-7 in vivo. J Cancer Ther 5:369–86
   PubMedGoogle Scholar
• Eggen S, Fagerland SM, Mørch Ý, et al. (2014). Ultrasound-enhanced drug delivery in prostate cancer xenografts by nanoparticles stabilizing microbubbles. J Control Release 187:39–49
   PubMed Web of Science ®Google Scholar
• Eom DW, Lee JH, Kim YJ, et al. (2014). Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells. BMB Rep. [Epub ahead of print]. pii: 2990
   PubMed Web of Science ®Google Scholar
• Galsky MD, Vogelzang NJ. (2010). Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 21:2135–44
   PubMed Web of Science ®Google Scholar
• Guo H, Xu Y, Fu Q. (2015). Curcumin inhibits growth of prostate carcinoma via miR-208-mediated CDKN1A activation. Tumour Biol. [Epub ahead of print]. doi: 10.1007/s13277-015-3592-y
   Web of Science ®Google Scholar
• Hadinoto K, Sundaresan A, Cheow WS. (2013). Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 85:427–43
   PubMed Web of Science ®Google Scholar
• Hajikarimi Z, Khoei S, Khoee S, et al. (2014). Evaluation of the cytotoxic effects of PLGA coated iron oxide nanoparticles as a carrier of 5-fluorouracil and mega-voltage X-ray radiation in DU145 prostate cancer cell line. IEEE Trans Nanobiosci 13:403–8
   PubMed Web of Science ®Google Scholar
• Healy SJ, Gorman AM, Mousavi-Shafaei P, et al. (2009). Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 625:234–46
   PubMed Web of Science ®Google Scholar
• Hoang B, Ernsting MJ, Murakami M, et al. (2014). Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer. Int J Pharm 471:224–33
   PubMed Web of Science ®Google Scholar
• Horie S. (2012). Chemoprevention of prostate cancer: soy isoflavones and curcumin. Korean J Urol 53:665–72
   PubMedGoogle Scholar
• Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA Cancer J Clin 61:69–90
   PubMed Web of Science ®Google Scholar
• Jin J, Sui B, Gou J, et al. (2014). PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells. PLoS One 9:e112200
   PubMed Web of Science ®Google Scholar
• Li J, Djenaba JA, Soman A, et al. (2012). Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001–2007. Prostate Cancer 2012:6913
   Google Scholar
• Lin SS, Huang HP, Yang JS, et al. (2008). DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade-and mitochondrial-dependent pathway. Cancer Lett 272:77–90
   PubMed Web of Science ®Google Scholar
• Liu C, Zhu Y, Lou W, et al. (2013). Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 73:418–27
   PubMed Web of Science ®Google Scholar
• Liu Q, Li J, Pu G, et al. (2015). Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy. Drug Deliv. [Epub ahead of print]. doi: 10.3109/10717544.2015.1031295
   Web of Science ®Google Scholar
• Luo Y, Ling Y, Guo W, et al. (2010). Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release 147:278–88
   PubMed Web of Science ®Google Scholar
• Mathur A, Abd Elmageed ZY, Liu X, et al. (2014). Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells. PLoS One 9:e103109
   PubMed Web of Science ®Google Scholar
• Mehta RS, Barlow WE, Albain KS, et al. (2012). Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367:435–44
   PubMed Web of Science ®Google Scholar
• Saengkrit N, Saesoo S, Srinuanchai W, et al. (2014). Influence of curcumin-loaded cationic liposome on anticancer activity for cervical cancer therapy. Colloids Surf B Biointerfaces 114:349–56
   PubMed Web of Science ®Google Scholar
• Schonthal AH. (2012). Targeting endoplasmic reticulum stress for cancer therapy. Front Biosci (Schol Ed) 4:412–31
   PubMedGoogle Scholar
• Sundram V, Chauhan SC, Ebeling M, et al. (2012). Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One 7:e35368
   PubMedGoogle Scholar
• Vaishampayan U, Hussain M. (2008). Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert Rev Anticancer Ther 8:269–81
   PubMed Web of Science ®Google Scholar
• van Oosterom AT, Schrijvers D, Schrijvers D. (1995). Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: clinical experience. Anticancer Drugs 6:356–68
   PubMed Web of Science ®Google Scholar
• Wei X, Zhou D, Wang H, et al. (2013). Effects of pyridine analogs of curcumin on growth, apoptosis and NF-κB activity in prostate cancer PC-3 cells. Anticancer Res 33:1343–50
   PubMed Web of Science ®Google Scholar
• Woo JH, Kim YH, Choi YJ, et al. (2003). Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 24:1199–208
   PubMed Web of Science ®Google Scholar
• Wu Y, Fabritius M, Ip C. (2009). Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer. Cancer Biol Ther 8:146–52
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Khan S, Maher DM, et al. (2014). Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 35:8635–48
   PubMed Web of Science ®Google Scholar
• Yang Q, Yang Y, Li L, et al. (2015). Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer. ACS Appl Mater Interfaces 7:6661–73
   PubMed Web of Science ®Google Scholar
• Zhang L, Chan JM, Gu FX, et al. (2008). Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2:1696–702
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu C, Armstrong C, et al. (2015). Anti-androgens inhibit ABCB1 efflux and ATPase activity and reverse docetaxel resistance in advanced prostate cancer. Clin Cancer Res 2015. [Epub ahead of print]. doi: 10.1158/1078-0432.CCR-15-0269
   Web of Science ®Google Scholar
• Zu S, Ma W, Xiao P, et al. (2015). Evaluation of docetaxel-sensitive and docetaxel-resistant proteomes in PC-3 cells. Urol Int 2015. [Epub ahead of print]. doi: 10.1159/000351263
   Google Scholar